Overview Financials News + Filings IR Vault Key Docs Charts Transactions Ownership Insiders
|
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Endo Pharmaceuticals | 1,394.0 | 1,678.0 | 1,657.8 | 1,467.6 | | | | |
| Qualitest | 730.7 | 633.3 | 566.9 | 146.5 | | | | |
| AMS | 492.2 | 330.1 | 300.3 | | | | | |
| Generics | | | | | 124.7 | | | |
| Other | | 174.4 | | 102.1 | 1,336.1 | | | |
| Total revenues [+] | 2,616.9 | 2,815.7 | 2,524.9 | 1,716.2 | 1,460.8 | 1,260.5 | 1,085.6 | 909.7 |
| Products | 492.2 | 504.5 | 300.3 | | | 1,260.5 | | |
| Other | 62.8 | 13.6 | 15.5 | 115.0 | 9.3 | | | |
| Revenue growth [+] | -7.1% | 11.5% | 47.1% | 17.5% | 15.9% | 16.1% | 19.3% | 10.9% |
| Endo Pharmaceuticals | -16.9% | 1.2% | 13.0% | | | | | |
| Qualitest | 15.4% | 11.7% | 286.9% | | | | | |
| AMS | 49.1% | 9.9% | | | | | | |
| Cost of goods sold | 1,039.5 | 1,135.7 | 948.1 | 504.8 | 754.6 | 267.2 | 217.4 | 208.9 |
| Gross profit | 1,577.4 | 1,680.1 | 1,576.8 | 1,211.5 | 706.2 | 993.3 | 868.2 | 700.8 |
| Gross margin | 60.3% | 59.7% | 62.5% | 70.6% | 48.3% | 78.8% | 80.0% | 77.0% |
| Selling, general and administrative | 849.3 | 864.3 | 783.9 | 547.6 | 534.5 | 488.1 | 411.9 | 346.3 |
| Research and development | 142.5 | 219.1 | 179.8 | 144.5 | 185.3 | 110.2 | 138.3 | 86.6 |
| Other operating expenses | 478.4 | 316.4 | | | -379.5 | | 0.9 | 31.3 |
| EBITDA [+] | 362.8 | 565.7 | 850.5 | 627.7 | 446.3 | 441.5 | 334.6 | 254.1 |
| EBITDA growth | -35.9% | -33.5% | 35.5% | 40.6% | 1.1% | 31.9% | 31.7% | -22.7% |
| EBITDA margin | 13.9% | 20.1% | 33.7% | 36.6% | 30.6% | 35.0% | 30.8% | 27.9% |
| Depreciation | 70.3 | 65.2 | 52.4 | 24.4 | 17.5 | 46.4 | 17.4 | 17.5 |
| EBITA | 292.5 | 500.5 | 798.1 | 603.3 | 428.9 | 395.0 | 317.2 | 236.6 |
| EBITA margin | 11.2% | 17.8% | 31.6% | 35.2% | 29.4% | 31.3% | 29.2% | 26.0% |
| Amortization of intangibles | 185.3 | 220.3 | 185.0 | 84.0 | 62.9 | | | |
| EBIT [+] | 107.1 | 280.2 | 613.1 | 519.3 | 365.9 | 395.0 | 317.2 | 236.6 |
| EBIT growth | -61.8% | -54.3% | 18.0% | 41.9% | -7.4% | 24.5% | 34.1% | -24.5% |
| EBIT margin | 4.1% | 9.9% | 24.3% | 30.3% | 25.1% | 31.3% | 29.2% | 26.0% |
| Non-recurring items [+] | 532.8 | 820.1 | 148.1 | 54.0 | -24.1 | 7.6 | | 26.0 |
| Asset impairment | 519.0 | 715.6 | 116.1 | 35.0 | 69.0 | 8.1 | | |
| Legal settlement | | 85.1 | | | | | | |
| In-process research & development | | | | | | -0.5 | | 26.0 |
| Interest expense, net [+] | 173.6 | 182.8 | 148.0 | 46.6 | 37.7 | 6.1 | -35.4 | 1.4 |
| Interest expense | 173.6 | 182.8 | 148.0 | 46.6 | 37.7 | 6.1 | | 1.4 |
| Interest income | | | | | | | 35.4 | |
| Other income (expense), net [+] | 39.7 | -7.7 | -10.5 | 1.9 | 7.4 | 10.5 | 0.6 | 24.6 |
| Other | 51.0 | -0.4 | 1.4 | 0.2 | -3.3 | -1.8 | 0.6 | |
| Pre-tax income | -559.6 | -730.4 | 306.4 | 420.7 | 359.7 | 391.8 | 353.3 | 233.7 |
| Income taxes | -24.1 | -36.4 | 112.1 | 133.7 | 93.3 | 136.5 | 125.8 | 95.9 |
| Tax rate | 4.3% | 5.0% | 36.6% | 31.8% | 25.9% | 34.8% | 35.6% | 41.0% |
| Minority interest | 52.9 | 52.3 | 54.5 | 28.0 | | | | |
| Earnings from continuing ops | -588.4 | -1,440.3 | 139.9 | 259.0 | 266.3 | 255.3 | 227.4 | 137.8 |
| Earnings from discontinued ops | -96.9 | 6.0 | 47.7 | | | | | |
| Net income | -685.3 | -1,434.3 | 187.6 | 259.0 | 266.3 | 255.3 | 227.4 | 137.8 |
| Net margin | -26.2% | -50.9% | 7.4% | 15.1% | 18.2% | 20.3% | 21.0% | 15.2% |
| |
| Basic EPS [+] | ($5.19) | ($12.45) | $1.20 | $2.23 | $2.27 | $2.07 | $1.70 | $1.03 |
| Growth | -58.3% | -1138.3% | -46.2% | -2.0% | 9.8% | 22.0% | 64.1% | -32.3% |
| Diluted EPS [+] | ($5.19) | ($12.45) | $1.15 | $2.20 | $2.27 | $2.06 | $1.69 | $1.03 |
| Growth | -58.3% | -1178.1% | -47.4% | -3.1% | 9.8% | 22.1% | 64.3% | -32.2% |
| |
| Shares outstanding (basic) [+] | 113.3 | 115.7 | 116.7 | 116.2 | 117.1 | 123.2 | 133.9 | 133.2 |
| Growth | -2.1% | -0.8% | 0.5% | -0.8% | -5.0% | -8.0% | 0.5% | 0.7% |
| Shares outstanding (diluted) [+] | 113.3 | 115.7 | 121.2 | 118.0 | 117.5 | 123.7 | 134.5 | 133.9 |
| Growth | -2.1% | -4.5% | 2.7% | 0.4% | -5.0% | -8.0% | 0.5% | 0.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|